Portal de Periódicos da CAPES

Consensus document on the primary prevention of cow’s milk protein allergy in infants aged less than 7 days

2022; Elsevier BV; Volume: 97; Issue: 1 Linguagem: Inglês

10.1016/j.anpede.2022.05.004

2341-2879

Juan José Díaz, Luis Blesa Baviera, Cristina Campoy, Beatriz Espín Jaime, María Rosaura Leis Trabazo, M. Mesa del Castillo, Rafael Martín Masot, Ana Martínez‐Cañavate Burgos, Antonio Martorell Aragonés, Manuel Molina Arias, Enriqueta Román Riechmann, Miguel Sáenz de Pipaón, Laura Valdesoiro Navarrete,

Asthma and respiratory diseases

Cow's milk protein allergy (CMPA) is the most frequent food allergy in the first year of life. There is no clear consensus regarding its prevention. A recommendation to avoid CMP in the first week of life as a preventive measure in all infants, regardless of their atopic risk, has recently been published. The purpose of this document is to issue a recommendation on the use of extensively hydrolyzed CMP formulas in the first week of life for the primary prevention of CMPA.A group of experts was formed with members proposed by the Spanish Association of Pediatrics (AEP), the Spanish Society of Clinical Immunology and Allergology and Pediatric Asthma (SEICAAP), the Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition (SEGHNP) and the Spanish Society of Neonatology (SENEO). The group conducted a critical review of the evidence on the subject published in the last 10 years.The search yielded 72 studies, of which 66 were rejected for not meeting the inclusion criteria. The final review included 6 documents: 3 clinical trials and 3 systematic reviews, 2 of them with meta-analysis. There was no evidence of a statistically significant reduction in the incidence of CMPA in the infants who received hypoallergenic formulae or exclusive breastfeeding.Based on the current evidence, it is not possible to draw clear conclusions about the effect of avoiding CMP in the first week of life for prevention of CMPA. Although there are data that suggest a certain beneficial effect of avoiding CMPA in atopic risk infants, these results are not conclusive enough to extend the recommendation to the general population.